Interviews

Having spent 30 years in the biopharmaceutical industry, Burton has witnessed monumental shifts in biomanufacturing. However, he reflected that “many of the original challenges remain, but in a new co

Highlighting the rapid proliferation of cell and gene therapies (CGTs), Hummersone described how his company seeks to support downstream processing for emerging therapies.